Log in

NASDAQ:CVETCovetrus Stock Price, Forecast & News

$23.08
-0.59 (-2.49 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$22.94
Now: $23.08
$24.99
50-Day Range
$17.38
MA: $20.18
$23.67
52-Week Range
$4.05
Now: $23.08
$24.99
Volume1.92 million shs
Average Volume1.60 million shs
Market Capitalization$2.58 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.85
Covetrus, Inc. engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded on April 13, 2018 and is headquartered in Melville, NY.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.05 out of 5 stars


Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryN/A
Current SymbolNASDAQ:CVET
CUSIPN/A
CIKN/A
Phone888-280-2221

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.98 billion
Cash Flow$10.79 per share
Book Value$11.20 per share

Profitability

Net Income$-1,019,000,000.00

Miscellaneous

Employees5,500
Market Cap$2.58 billion
Next Earnings DateN/A
OptionableNot Optionable
$23.08
-0.59 (-2.49 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CVET News and Ratings via Email

Sign-up to receive the latest news and ratings for CVET and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Covetrus (NASDAQ:CVET) Frequently Asked Questions

How has Covetrus' stock been impacted by COVID-19 (Coronavirus)?

Covetrus' stock was trading at $9.04 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CVET shares have increased by 155.3% and is now trading at $23.08.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Covetrus?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Covetrus
.

How were Covetrus' earnings last quarter?

Covetrus Inc (NASDAQ:CVET) announced its quarterly earnings data on Tuesday, August, 11th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.19. The company earned $1.03 billion during the quarter, compared to analyst estimates of $892.90 million. Covetrus had a negative net margin of 24.05% and a positive return on equity of 4.84%. The business's revenue for the quarter was up 1.7% on a year-over-year basis. During the same period last year, the company earned ($0.09) earnings per share.
View Covetrus' earnings history
.

What price target have analysts set for CVET?

4 analysts have issued 1-year price targets for Covetrus' stock. Their forecasts range from $11.00 to $21.00. On average, they anticipate Covetrus' stock price to reach $16.00 in the next year. This suggests that the stock has a possible downside of 30.7%.
View analysts' price targets for Covetrus
.

Has Covetrus been receiving favorable news coverage?

News coverage about CVET stock has trended somewhat positive this week, according to InfoTrie. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Covetrus earned a coverage optimism score of 1.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about Covetrus
.

Are investors shorting Covetrus?

Covetrus saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 17,740,000 shares, an increase of 18.5% from the January 15th total of 14,970,000 shares. Based on an average trading volume of 1,610,000 shares, the days-to-cover ratio is currently 11.0 days. Approximately 18.2% of the shares of the stock are short sold.
View Covetrus' Short Interest
.

Who are some of Covetrus' key competitors?

What other stocks do shareholders of Covetrus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Covetrus investors own include NVIDIA (NVDA), Pfizer (PFE), Taiwan Semiconductor Mfg. (TSM), Advanced Micro Devices (AMD), Activision Blizzard (ATVI), Chegg (CHGG), Evolent Health (EVH), General Mills (GIS), IDEXX Laboratories (IDXX) and Livongo Health (LVGO).

Who are Covetrus' key executives?

Covetrus' management team includes the following people:
  • Benjamin J. Shaw, President, Chief Executive Officer & Director
  • Christine Tomlinson Komola, Chief Financial Officer & Executive Vice President
  • Matthew Leonard, Executive VP & President-North America
  • Jim Young, Chief Human Resources Officer & Senior VP
  • Erin Powers Brennan, Secretary, Senior Vice President & General Counsel

What is Covetrus' stock symbol?

Covetrus trades on the NASDAQ under the ticker symbol "CVET."

Who are Covetrus' major shareholders?

Covetrus' stock is owned by many different institutional and retail investors. Top institutional investors include BNP PARIBAS ASSET MANAGEMENT Holding S.A. (1.30%), Palisade Capital Management LLC NJ (0.82%), Principal Financial Group Inc. (0.66%), New York State Common Retirement Fund (0.21%), Swiss National Bank (0.20%) and WINTON GROUP Ltd (0.15%). Company insiders that own Covetrus stock include Benjamin Shaw, Betsy S Atkins, David Christopher Dollar, Edward Mcnamara, Erin Powers Brennan and Timothy Ludlow.
View institutional ownership trends for Covetrus
.

Which institutional investors are selling Covetrus stock?

CVET stock was sold by a variety of institutional investors in the last quarter, including BNP PARIBAS ASSET MANAGEMENT Holding S.A., Russell Investments Group Ltd., UBS Group AG, State Board of Administration of Florida Retirement System, Principal Financial Group Inc., New York State Common Retirement Fund, Westside Investment Management Inc., and M&T Bank Corp. Company insiders that have sold Covetrus company stock in the last year include Edward Mcnamara, and Timothy Ludlow.
View insider buying and selling activity for Covetrus
.

Which institutional investors are buying Covetrus stock?

CVET stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Tuttle Tactical Management, WINTON GROUP Ltd, Swiss National Bank, Teza Capital Management LLC, Centric Wealth Management, New York State Teachers Retirement System, and ProShare Advisors LLC. Company insiders that have bought Covetrus stock in the last two years include Benjamin Shaw, and Erin Powers Brennan.
View insider buying and selling activity for Covetrus
.

How do I buy shares of Covetrus?

Shares of CVET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Covetrus' stock price today?

One share of CVET stock can currently be purchased for approximately $23.08.

How big of a company is Covetrus?

Covetrus has a market capitalization of $2.58 billion and generates $3.98 billion in revenue each year. The company earns $-1,019,000,000.00 in net income (profit) each year or $0.79 on an earnings per share basis. Covetrus employs 5,500 workers across the globe.

What is Covetrus' official website?

The official website for Covetrus is www.henryscheinvet.com.

How can I contact Covetrus?

Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The company can be reached via phone at 888-280-2221 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.